Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis - PubMed
5 days ago
- #prognostic model
- #genomic profiling
- #myelofibrosis
- Secondary myelofibrosis (SMF) is a late stage of polycythemia vera and essential thrombocythemia.
- The MYelofibrosis SECondary to PV and ET (MYSEC) Prognostic Model (MYSEC-PM) defines overall survival (OS) in SMF.
- Next-generation sequencing panel testing in 644 patients identified ASXL1, TET2, and DNMT3A as the most frequent cancer gene variants (CGVs).
- Specific molecular profiles (U2AF1, TP53, SRSF2 variants) significantly affect OS, with median OS ranging from 4.1 to 8.4 years.
- The MYSEC-molecular prognostic model (MYSEC-mPM) categorizes SMF patients into four risk groups with distinct OS outcomes.
- Incorporating cytogenetics (complex/monosomal karyotype) further enhances survival prediction via the karyotype-enhanced MYSEC-kmPM.
- Genomic and cytogenetic profiling improves SMF survival prediction beyond the MYSEC-PM.